About this Journal Submit a Manuscript Table of Contents
Case Reports in Endocrinology
Volume 2012 (2012), Article ID 645914, 5 pages
http://dx.doi.org/10.1155/2012/645914
Case Report

A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment

1First Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
2Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

Received 14 August 2012; Accepted 9 September 2012

Academic Editors: G. Aimaretti, B. K. Irons, and W. V. Moore

Copyright © 2012 Haruko Morokuma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Heaney, “Pituitary carcinoma: difficult diagnosis and treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 12, pp. 3649–3660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman, “Clinical review: diagnosis and management of pituitary carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 3089–3099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Dudziak, J. Honegger, A. Bornemann, M. Horger, and K. Müssig, “Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature,” vol. 96, no. 9, pp. 2665–2669, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Pernicone, B. W. Scheithauer, T. J. Sebo et al., “Pituitary carcinoma: a clinicopathologic study of 15 cases,” Cancer, vol. 79, no. 4, pp. 804–812, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Thapar, B. W. Scheithauer, K. Kovacs, P. J. Pernicone, and E. R. Laws, “p53 Expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions,” Neurosurgery, vol. 38, no. 4, pp. 765–771, 1996. View at Scopus
  6. K. Thapar, K. Kovacs, B. W. Scheithauer et al., “Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody,” Neurosurgery, vol. 38, no. 1, pp. 99–107, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. A. I. McCormack, J. A. H. Wass, and A. B. Grossman, “Aggressive pituitary tumours: Role of temozolomide and the assessment of MGMT status,” European Journal of Clinical Investigation, vol. 41, pp. 1133–1148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Raverot, F. Castinetti, E. Jouanneau et al., “Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment,” Clinical Endocrinology, vol. 76, no. 6, pp. 769–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Esteller, J. Garcia-Foncillas, E. Andion et al., “Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents,” New England Journal of Medicine, vol. 343, no. 19, pp. 1350–1354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Ekeblad, A. Sundin, E. T. Janson et al., “Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors,” Clinical Cancer Research, vol. 13, no. 10, pp. 2986–2991, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Lim, H. Shahinian, M. M. Maya, W. Yong, and A. P. Heaney, “Temozolomide: a novel treatment for pituitary carcinoma,” Lancet Oncology, vol. 7, no. 6, pp. 518–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Raverot, N. Sturm, F. De Fraipont et al., “Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 10, pp. 4592–4599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Losa, E. Mazza, M. R. Terreni et al., “Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases,” European Journal of Endocrinology, vol. 163, no. 6, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Thearle, P. U. Freda, J. N. Bruce, S. R. Isaacson, Y. Lee, and R. L. Fine, “Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor,” Pituitary, vol. 14, pp. 418–424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Takeshita, N. Inoshita, M. Taguchi et al., “High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease,” European Journal of Endocrinology, vol. 161, no. 4, pp. 553–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Wick, M. Platten, and M. Weller, “New (alternative) temozolomide regimens for the treatment of glioma,” Neuro-Oncology, vol. 11, no. 1, pp. 69–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Hegi, L. Liu, J. G. Herman et al., “Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4189–4199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. E. Fadul, A. L. Kominsky, L. P. Meyer et al., “Long-term response of pituitary carcinoma to temozolomide. Report of two cases,” Journal of Neurosurgery, vol. 105, no. 4, pp. 621–626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. V. Syro, H. Uribe, L. C. Penagos et al., “Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm,” Clinical Endocrinology, vol. 65, no. 4, pp. 552–553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. M. Bush, J. A. Longtine, T. Cunningham et al., “Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. E280–E290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. L. M. Neff, M. Weil, A. Cole et al., “Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists,” Pituitary, vol. 10, no. 1, pp. 81–86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kurzen, S. Schmitt, H. Näher, and T. Möhler, “Inhibition of angiogenesis by non-toxic doses of temozolomide,” Anti-Cancer Drugs, vol. 14, no. 7, pp. 515–522, 2003. View at Publisher · View at Google Scholar · View at Scopus